XW043M7Introduction of Brexucabtagene Autoleucel Immunotherapy into Central Vein, Percutaneous Approach, New Technology Group 7

New Technology›Anatomical Regions›Introduction
  • Billable / Specific Code
ICD-10-PCS XW043M7
CMS Source: FY 2027 ICD-10-PCS dataset. Effective Oct 1, 2026 – Sep 30, 2027.FacebookXLinkedInPrint

XW043M7 is a billable ICD-10-PCS procedure code for Introduction of Brexucabtagene Autoleucel Immunotherapy into Central Vein, Percutaneous Approach, New Technology Group 7. It is valid on HIPAA claims for fiscal year 2027 (October 1, 2026 through September 30, 2027).

Code Identity

ICD-10-PCS Code
XW043M7
Billable Status
Yes — Valid for Submission
Code Describes
Introduction of Brexucabtagene Autoleucel Immunotherapy into Central Vein, Percutaneous Approach, New Technology Group 7
Short Description
Introduce Brexucab in Central Vein, Perc, New Tech 7
Parent Code
XW0

PCS Table Breakdown

Each ICD-10-PCS code is built from seven characters, each an axis of the procedure. Hover or tap the icons for the official CMS definitions.

PositionDesignationValueMeaning
1SectionXNew Technology
2Body SystemWAnatomical Regions
3Operation0Introduction
4BodyPart4Central Vein
5Approach3Percutaneous
6Device/Substance/TechnologyMBrexucabtagene Autoleucel Immunotherapy
7Qualifier7New Technology Group 7

Similar Procedure Codes

Questions About XW043M7

Is XW043M7 a billable code?

Yes. This is a complete seven-character ICD-10-PCS code, specific enough to report Introduction of Brexucabtagene Autoleucel Immunotherapy into Central Vein, Percutaneous Approach, New Technology Group 7 on inpatient claims from October 1, 2026 through September 30, 2027.

What do the characters in XW043M7 mean?

The code breaks down character by character: the 1st character X is the Section (New Technology); the 2nd character W is the Body System (Anatomical Regions); the 3rd character 0 is the Operation (Introduction); the 4th character 4 is the BodyPart (Central Vein); the 5th character 3 is the Approach (Percutaneous); the 6th character M is the Device/Substance/Technology (Brexucabtagene Autoleucel Immunotherapy); the 7th character 7 is the Qualifier (New Technology Group 7).